Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioInvent International AB ( (SE:BINV) ) has issued an announcement.
BioInvent International AB has called its Annual General Meeting for 29 April 2026 at Elite Hotel Ideon in Lund, Sweden, offering shareholders the option to participate either in person or by advance postal voting in line with its Articles of Association. Shareholders must be registered with Euroclear Sweden by 21 April and comply with specified notification, proxy and voting rights registration procedures, particularly for nominee-registered shares.
The AGM agenda includes presentation of the 2025 annual and group financial reports, decisions on result appropriation, discharge of the board and CEO from liability, and approval of the remuneration report. The nomination committee also proposes decisions on board size, directors’ and auditor’s fees, and the re-election of board members Natalie Berner, Leonard Kruimer and Nanna Lüneborg, underscoring continuity in the company’s governance structure.
The most recent analyst rating on (SE:BINV) stock is a Hold with a SEK23.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a Swedish biotechnology company based at Ideon Science Park in Lund, focusing on the discovery and development of antibody-based cancer therapies. The company targets oncology indications and collaborates with international partners to advance its immuno-oncology pipeline and strengthen its position in the global biotech market.
Average Trading Volume: 107,455
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.46B
See more data about BINV stock on TipRanks’ Stock Analysis page.